Report from the extra ordinary shareholder’s meeting in Peptonic Medical (publ)
The extra ordinary shareholder’s meeting resolved to approve the decision by the Board of Directors to exercise the option to acquire the remaining outstanding shares in Lunde Group Oy by way of a directed rights issue at a value or approx. 12.5 MSEK.In conjunction with the acquisition of the majority of the shares in Lune Group Oy (“Lune”) Peptonic Medical (“Company” or “Peptonic”) was granted an option to acquire the balance of the share in Lune. On July 7th, 2020, Peptonic informed the sellers that it intends to exercise the option. The value or the shares amounts to 1.2 MEUR (approx. 12.